FindMyKOL
Clinical trialNCT04118010CompletedPhase 4Interventional

Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis

NCT04118010 is a phase 4 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is completed. It studies Inulin, Placebo Inulin, Placebo vitamin D3 and Vitamin D3 in Cystic Fibrosis and Dysbiosis. The registry lists an enrollment of 40 participants at 1 site in 1 country. The registry lists a start date of 13 Mar 2020 and a primary completion date of 31 Dec 2022.

SponsorEmory University →Enrollment40Cystic FibrosisDysbiosis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04118010
FieldValue
Registry IDNCT04118010
StatusCompleted
PhasePhase 4
Study typeInterventional trial
Lead sponsorEmory University
Enrollment40
Registered sites1
Countries1
ConditionsCystic Fibrosis and Dysbiosis
DrugsInulin, Placebo Inulin, Placebo vitamin D3 and Vitamin D3
Start13 Mar 2020
Primary completion31 Dec 2022
Study completion31 Dec 2022
Last update posted7 Feb 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study will assess if administration of high-dose vitamin D and a commonly used prebiotic (inulin) is effective to reduce gastrointestinal dysbiosis and to improve critical intestinal functions in Cystic Fibrosis with the additive or synergistic effects of the combination of vitamin D + inulin.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States1 site
  • Emory Clinic

    Atlanta

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 siteGA1HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

InulinPlacebo InulinPlacebo vitamin D3Vitamin D3
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04118010

Each answer restates registry values shown on this page.

What is NCT04118010?

NCT04118010 is a phase 4 interventional trial sponsored by Emory University. It studies Inulin, Placebo Inulin, Placebo vitamin D3 and Vitamin D3 in Cystic Fibrosis and Dysbiosis.

Who leads NCT04118010?

The registry names Vin Tangpricha, MD (principal investigator, Emory University) as the overall official.

Where does NCT04118010 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT04118010 study?

The registered drug and biological interventions are Inulin, Placebo Inulin, Placebo vitamin D3 and Vitamin D3.

When did NCT04118010 end?

The registry lists a primary completion date of 31 Dec 2022 and a study completion date of 31 Dec 2022. The sponsor last updated the record on 7 Feb 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.